Relpax Related Published Studies
Well-designed clinical trials related to Relpax (Eletriptan)
Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. [2007.02]
Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. [2006.03]
Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. [2005.09]
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. [2005.02]
No effect of eletriptan administration during the aura phase of migraine. [2004.10]
Effect of high-dose intravenous eletriptan on coronary artery diameter. [2004.07]
Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials. [2004.03]
Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. [2003.12]
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. [2003.11]
A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. [2003.07]
Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. [2003.07]
Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. [2003.03]
Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. [2003.03]
Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. [2002.10.22]
Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. [2002.05]
The pharmacokinetics and safety of single escalating oral doses of eletriptan. [2002.05]
Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. [2002.02]
Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. [2002]
Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. [2001.12]
Effectiveness of eletriptan in reducing time loss caused by migraine attacks. [2000.12]
Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. [2000.01.11]
Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. [2000.01]
Well-designed clinical trials possibly related to Relpax (Eletriptan)
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. [2011.04]
Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. [2011.01]
Frovatriptan for prophylactic treatment of cluster headache: lessons for future
trial design. [2011]
The efficacy and tolerability of a fixed combination of acetylsalicylic acid,
paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup
analysis from a multicentre, randomized, double-blind, single-dose,
placebo-controlled parallel group study. [2011]
Large-scale screening and subsequent effects of migraine treatment on the work floor in the Netherlands. [2009.06]
Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? [2006.04]
Multiple attack study on the available triptans in Italy versus placebo. [2005.07]
Current perspectives on effective migraine treatments: are small clinical differences important for patients? [2003]
Other research related to Relpax (Eletriptan)
Perimenstrual eletriptan prevents menstrual migraine: an open-label study. [2010.04]
Eletriptan. [2009.12]
Halide salts of antimigraine agents eletriptan and naratriptan. [2008.12]
Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. [2008.02]
Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. [2008.01]
Patient satisfaction with eletriptan in the acute treatment of migraine in primary care. [2007.10]
WITHDRAWN: Eletriptan for acute migraine. [2007.07.18]
Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. [2007.05]
Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. [2007.04]
Eletriptan: a review and new perspectives. [2006.10]
Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. [2006.07]
Safety and efficacy of eletriptan in the treatment of acute migraine. [2006.01]
Eletriptan: a review of its use in the acute treatment of migraine. [2006]
Spotlight on eletriptan in migraine. [2006]
Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries. [2005.11]
Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. [2005.09]
Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. [2005.09]
Eletriptan review. [2005.04]
[Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal] [2005.01]
Eletriptan in migraine. [2005.01]
[Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies] [2004.10]
Eletriptan for the short-term prophylaxis of cluster headache. [2004.04]
Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. [2004.03]
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. [2004.02]
Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. [2003.10]
Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. [2003.10]
[Pharmacological, pharmacokinetic and clinical profile of eletriptan (Relpax), a new triptan for migraine] [2003.07]
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. [2003.07]
Eletriptan Pfizer. [2002.09]
Eletriptan. [2001.10]
Eletriptan: pharmacological differences and clinical results. [2001]
Eletriptan for acute migraine. [2001]
Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. [2000.12]
Determination of eletriptan in plasma and saliva using automated sequential trace enrichment of dialysate and high-performance liquid chromatography. [1999.12]
Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. [1999.07]
Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. [1999.07]
Other possibly related research studies
TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. [2004.09]
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. [2004.05]
Cost considerations of acute migraine treatment. [2004.03]
The evolving management of migraine. [2003.06]
Comparative aspects of triptans in treating migraine. [2001]
Tripstar: a comprehensive patient-based approach to compare triptans. [2002.01]
Acute treatment of migraine and the role of triptans. [2001.03]
Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. [2001.11.17]
Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans). [2001.07]
Current and emerging second-generation triptans in acute migraine therapy: a comparative review. [2000.07]
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. [1999.06]
Gateways to clinical trials. [2005.10]
[The role of triptans and analgesics for primary headache treatment] [2005.10]
Gateways to clinical trials. [2005.07]
Gateways to clinical trials. [2005.05]
Gateways to clinical trials. [2005.06]
[Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans.] [2005.07]
Defining response in migraine: which endpoints are important? [2005]
Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. [2005.05]
Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. [2005]
[Economic evaluation of acute migraine attack treatment with triptans in Spain] [2005.04]
How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. [2005.03]
The use of multiattribute decision models in evaluating triptan treatment options in migraine. [2005.09]
Triptan nonresponder studies: implications for clinical practice. [2005.02]
Correlation between lipophilicity and triptan outcomes. [2005.01]
Gateways to clinical trials. [2004.11]
Gateways to clinical trials. [2004.09]
Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). [2004.09]
Gateways to clinical trials. [2004.07]
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. [2004.06]
Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. [2004.05]
Gateways to clinical trials. [2004.01]
Newer formulations of the triptans: advances in migraine management. [2003]
Migraine: diagnosis and management. [2003.09]
Safety profile of the triptans. [2003.03]
|
